The natural history of benign and potentially malignant ventricular arrhythmias with special reference to nonsustained ventricular tachycardia.
The natural history of benign and potentially malignant ventricular arrhythmias with special reference to nonsustained ventricular tachycardia.
复制标题
良性和潜在恶性室性心律失常的自然史，特别是非持续性室性心动过速。
DOI：
10.1016/0002-8703(88)90139-1
复制
发表时间：
1988
影响因子：
4.8
通讯作者：
Young,JB
中科院分区：
文献类型：
--
作者：
Pratt,CM;Francis,M;Mahler,S;Aogaichi,K;Keus,P;Young,JB
动态心电图记录通常用于识别心源性猝死风险增加的患者，并监测抗心律失常药物治疗期间室性心律失常的变化。先前报告称，在非危及生命的室性心律失常患者中，初始基线期间确定的心律失常频率在第二个安慰剂监测期内发生变化，但尚未检查这适用于非持续性室性心动过速患者的程度。为了将这些观察结果扩展到具有潜在致死性室性心律失常的患者，我们研究了53例患者，这些患者参加了两项抗心律失常药物试验，其中一项试验在成功抑制心律失常后平均16个月引入了第二个单盲安慰剂期（安慰剂脉冲）。53例患者中有38例在初始基线（安慰剂I）期间记录到非持续性室性心动过速，63%的患者平均每天发作≥10次。在两个安慰剂治疗期之间，心律失常的发生率显著降低：室性早搏为55%，配对为77%（分别为p< 0.001）。在38例非持续性室性心动过速患者中，有72%的患者减少（892 ± 531 vs 245 ± 18次VT/天，安慰剂I vs II;p= 0.0001），其中32%的患者在第二个安慰剂治疗期间完全抑制了非持续性室性心动过速。本试验的结果将我们先前观察到的心律失常频率的长期自发性变化扩展到有症状的、潜在致死性室性心律失常患者，并支持定期重新评估基线心律失常频率以确定是否继续需要抗心律失常治疗的建议。这些观察结果不能扩展至危及生命的心律失常（持续性室性心动过速、心脏骤停或室颤）患者。
Ambulatory ECG recordings are routinely used to identify patients at increased risk of sudden cardiac death and to monitor changes in ventricular arrhythmias during antiarrhythmic drug therapy. The arrhythmia frequency established during the initial baseline has previously been reported to change during a second placebo monitoring period in patients with non-life-threatening ventricular arrhythmias, but the extent to which this applies to patients with nonsustained ventricular tachycardia has not been examined. To extend these observations to patients with potentially lethal ventricular arrhythmias, we studied 53 patients enrolled in one of two investigational antiarrhythmic drug trials that introduced a second single-blind placebo period (placebo-pulse) an average of 16 months after successful arrhythmia suppression. Thirty-eight of the 53 patients had runs of nonsustained ventricular tachycardia recorded during the initial baseline (placebo I) period, with 63% averaging ≥10 runs per day. There was a marked reduction in the arrhythmia frequencies between the two placebo periods: 55% for ventricular premature beats, and 77% for pairs (p< 0.001, respectively). Of the 38 patients with nonsustained ventricular tachycardia, there was a 72% reduction (892 ± 531 vs 245 ± 18 runs of VT/day, placebo I vs II;p= 0.0001), with 32% having total suppression of nonsustained ventricular tachycardia during the second placebo period. The results of this trial extend our previous observations of long-term spontaneous changes in arrhythmia frequency to patients with symptomatic, potentially lethal ventricular arrhythmia and support the recommendation for periodic reassessment of baseline arrhythmia frequency to determine the continued need for antiarrhythmic therapy. These observations cannot be extended to patients with life-threatening arrhythmias (sustained ventricular tachycardia, cardiac arrest, or ventricular fibrillation).
BALB/c 小鼠对流感病毒血凝素免疫反应中抗体多样性的产生。
影响因子：
15.3
作者：
L. Staudt;W. Gerhard
通讯作者：
W. Gerhard
针对属特异性衣原体抗原的人单克隆抗体，由 EBV 转化的 B 细胞产生。
影响因子：
4.4
作者：
A. Rosén;K. Persson;G. Klein
通讯作者：
G. Klein
Galinsoga 花叶病毒的颗粒形态学和细胞病理学
DOI：
--
发表时间：
1983
期刊：
影响因子：
--
作者：
T. Hatta;R. Francki;C. Grivell
通讯作者：
C. Grivell